A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies

Model scores of the 29,894 trials active now.

Model score 12% for any early termination, 1% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 16% of the time (1,938 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2023-11-01. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: priormritreatment withdefinedmetastatic
  Phrases that lowered it: participantdoseparticipantsadministeredmg
• Phase: 1 (lowers risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: no earlier finished trials (lowers risk) · Sponsor's track record
• Has a data monitoring committee: not given (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Disease area, cancer: Yes (raises risk) · Disease area
• Number of arms: 4 (lowers risk) · Design
• Drug's FAERS reports with a death: 21.7% (raises risk) · Drug's FDA history
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Design: sequential (lowers risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Drug's FAERS reports before start: 88327 (lowers risk) · Drug's FDA history
• Disease area, respiratory: Yes (raises risk) · Disease area
• Drug's FAERS reports in the prior 12 months: 17298 (lowers risk) · Drug's FDA history
• Disease area, dermatology: Yes (raises risk) · Disease area

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma NCT03502330 · started 2018 · scored riskier than 52% of active trials completed
• Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLC NCT02382406 · started 2015 · scored riskier than 92% of active trials terminated
• Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC) NCT03769467 · started 2019 · scored riskier than 67% of active trials terminated
• A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and Cemiplimab in Patients With Advanced Solid Tumors NCT03192345 · started 2017 · scored riskier than 39% of active trials completed
• Study of Epacadostat (INCB024360) Alone and In Combination With Pembrolizumab (MK-3475) With Chemotherapy and Pembrolizumab Without Chemotherapy in Participants With Advanced Solid Tumors (MK-3475-434) NCT02862457 · started 2016 · scored riskier than 36% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.